Patient information Australia

The DRA in Venezuela allows prescription drugs to be advertised in the press on a onetime basis as an announcement that the dmg is now registered in Venezuela. Information presented in the promotion and advertising materials must be based on the product information, as specified in the summary of product characteristics (SPC), approved at the time of registration. In all countries except Australia, patient information leaflets and labels are also subject to approval. In Australia, although approval is not needed, the information must not conflict with the approved product information. 

McClennan et al. conducted a prospective 2-month intervention study to determine clinical outcomes associated with pharmacist interventions at a tertiary referral cancer institute in Australia. Clinical pharmacists documented clinical interventions and relevant patient information which were assessed by an independent pharmacist. Members of the healthcare team reviewed and discussed medical progress notes to determine outcomes. Of 674 total interventions that were documented during the study, outcomes were assessed for 10% of the interventions reported 90% of the interventions led to documented clinical benefit. Pharmacist interventions most frequently consisted of initiating changes in drug therapy associated with antiemetic, antimicrobial, and analgesic agents. 

THE AUTHOR, CHARLES VINCENT, ACKNOWLEDGES THE VALUABLE WORK OF THE OFFICE OF SAFETY AND QUALITY IN HEALTHCARE (OSQH) AT THE WESTERN AUSTRALIAN DEPARTMENT OF HEALTH IN DEVELOPING THE WA OPEN DISCLOSURE POLICY COMMUNICATION AND DISCLOSURE REQUIREMENTS FOR HEALTH PROFESSIONALS WORKING IN WESTERN AUSTRALIA (2009) ON WHICH THIS OPEN DISCLOSURE PATIENT INFORMATION PAMPHLET IS BASED. CHARLES VINCENT THANKS THE OSQH FOR PERMISSION TO USB THIS DOCUMENT)... 

---